Treatment Information


Prostate Cancer treatment details. Biologic therapy.

University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Pittsburgh, PA
Treatments:Biologic therapyHospital:University of Pittsburgh School of Medicine
Date:Nov 2008


Patients: This phase 3 study involved 941 patients with non-metastatic, hormone-refractory prostate cancer. These men ranged in age from 47 to 93 years of age. The average time from their initial diagnosis of prostate cancer was a little over 7 years.

Treatment: These patients were treated with the biological therapy atrasentan or placebo. A placebo is an inactive substance given in the same form as the active drug.

Toxicity: Patients in both groups died; 22 in the atrasentan group and 16 in the placebo group. Toxicities included peripheral edema, nasal congestion, fatigue, headache, pain, and constipation. Heart failure occurred in 6.7% of patients treated with atrasentan and 3% of those treated with placebo.

Results: The median overall survival was 48.55 months (1477 days) in the group treated with atrasentan and 46.12 months (1403 days) in the group treated with placebo.

Support: This study was supported by research funds from Abbott Laboratories, which developed atrasentan.

Correspondence: Dr. Joel B. Nelson